Rallybio Corporation (RLYB)

US — Healthcare Sector
Peers: INTS  SONN  ITRM  TAOX  IBIO  KLTO  CVKD  XCUR  BOLD  QTTB 

Automate Your Wheel Strategy on RLYB

With Tiblio's Option Bot, you can configure your own wheel strategy including RLYB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
RLYB
Published: March 04, 2026 by: Business Wire
Sentiment: Neutral

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the me.

Read More
image for news Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
RLYB
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative

Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.

Read More
image for news RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
RLYB
Published: April 08, 2025 by: Benzinga
Sentiment: Negative

Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Read More
image for news Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

About Rallybio Corporation (RLYB)

  • IPO Date 2021-07-29
  • Website https://www.rallybio.com
  • Industry Biotechnology
  • CEO Martin W. MacKay
  • Employees 15
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.